Pre-Digested MAG Nutrition for Exocrine Pancreatic Insufficiency

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current treatments for exocrine pancreatic insufficiency (EPI), such as pancreatic enzyme replacement therapy (PERT), fail to adequately address malabsorption and malnutrition, particularly in conditions like cystic fibrosis, leading to suboptimal quality of life and nutritional challenges.

Innovation Solution

Development of nutritional compositions stabilized through aseptic ultra-high temperature treatment, comprising hydrolyzed protein and monoacylglycerols (MAG) as a significant portion of total fat, optionally with MCT and fatty acids, designed to be shelf-stable and require no pancreatic enzymes for digestion.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If pancreatic enzymes are added directly into food, then digestion capability is improved, but the formula becomes unstable and digests in an uncontrolled manner

Engineering Contradiction:
Improvedigestion capabilityVSAvoidformula stability
Core Design Contradiction:
Ease of manufactureVSStability of the object's composition

Solution Approach 1:

The patent applies preliminary action by pre-digesting the formula during manufacturing to achieve the desired level of di- and tri-peptides before consumption. This allows the nutritional formula to be prepared in advance with controlled enzymatic hydrolysis, eliminating the need to add enzymes at the point of use and preventing uncontrolled digestion while maintaining formula stability during storage.

Inventive Principle:
Principle #10Preliminary action

2Productivity

If protein is hydrolyzed to increase peptide levels, then nutrient absorption is improved, but the formula becomes bitter

Engineering Contradiction:
Improvenutrient absorptionVSAvoidbitterness
Core Design Contradiction:
ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent applies parameter changes by carefully controlling the degree of protein hydrolysis to achieve optimal levels of di- and tri-peptides while minimizing the formation of bitter-tasting smaller peptides and free amino acids. By adjusting hydrolysis parameters such as enzyme type, reaction time, temperature, and pH, the formula achieves high nutrient absorption capability while maintaining acceptable sensory properties.

Inventive Principle:
Principle #35Parameter changes

3Productivity

If fat is pre-digested to improve absorption, then nutrient availability is improved, but the formula becomes hyperosmolar

Engineering Contradiction:
Improvenutrient availabilityVSAvoidosmolarity
Core Design Contradiction:
ProductivityVSQuantity of substance

Solution Approach 1:

The patent applies parameter changes by controlling the extent of fat hydrolysis to produce mono- and di-glycerides while avoiding excessive breakdown that would create hyperosmolar conditions. By optimizing lipase treatment parameters including enzyme selection, reaction conditions, and hydrolysis degree, the formula achieves improved fat absorption through pre-digested fat components while maintaining osmolarity within acceptable limits for safe consumption.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The compositions effectively enhance nutrient absorption, improve quality of life, and address malnutrition by providing a stable, pre-digested nutritional solution suitable for patients with EPI, including those with cystic fibrosis.

Implementation Method 1

The nutritional compositions are preferably subjected to aseptic ultra-high temperature treatment (UHT), such as indirect UHT or direct UHT

Methodology Applied
Scientific EffectUltra-high temperature treatment: Heating

Implementation Method 2

the practice today is to not add pancreatic enzymes into the food directly because it will digest the formula in an uncontrolled manner

Methodology Applied
Scientific EffectEnzymatic hydrolysis: Hydrolysis

Data Source

PatentUS12433316B2Compositions and methods for treatment of exocrine pancreatic insufficiency (EPI)
Publication Date: 2025.10.07 SOCIETE DES PRODUITS NESTLE SA

AI summary

A method of treating exocrine pancreatic insufficiency includes administering to an individual in need thereof (e.g., an individual with cystic fibrosis) an effective amount of an enteral composition having a total protein consisting essentially of hydrolyzed protein and a total fat containing monoacylglycerols (MAG) that are at least about 30 wt. % of the total fat, and the total fat optionally further contains medium chain triglycerides (MCT) and/or fatty acids. In one particular non-limiting embodiment, about 60 wt. % of the total fat is from MCT and about 40 wt. % of the total fat is from MAG; in another particular non-limiting embodiment, the total fat is MAG with free fatty acids (esterified and/or bound) without MCT; and in yet another particular non-limiting embodiment, the total fat is MAG alone without MCT.